Insider Trading Alert - TIF, CRM And IRWD Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, May 30, 2014, 127 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $34.87 to $852,403,612.06.

Highlighted Stocks Traded by Insiders:

Tiffany (TIF) - FREE Research Report

Berger Gross Victoria, who is Senior Vice President at Tiffany, sold 500 shares at $97.64 on May 30, 2014. Following this transaction, the Senior Vice President owned 36,068 shares meaning that the stake was reduced by 1.37% with the 500-share transaction.

Singer Robert S, who is Director at Tiffany, sold 2,000 shares at $98.25 on May 30, 2014. Following this transaction, the Director owned 7,761 shares meaning that the stake was reduced by 20.49% with the 2,000-share transaction.

The shares most recently traded at $98.67, up $0.42, or 0.43% since the insider transaction. Historical insider transactions for Tiffany go as follows:

  • 4-Week # shares sold: 534
  • 12-Week # shares sold: 2,304
  • 24-Week # shares sold: 2,304

The average volume for Tiffany has been 1.3 million shares per day over the past 30 days. Tiffany has a market cap of $12.8 billion and is part of the services sector and specialty retail industry. Shares are up 7.15% year-to-date as of the close of trading on Friday.

Tiffany & Co., through its subsidiaries, designs, manufactures, and retails jewelry worldwide. The company operates through Americas, Asia-Pacific, Japan, Europe, and Other segments. The stock currently has a dividend yield of 1.53%. The company has a P/E ratio of 57.3. Currently, there are 7 analysts who rate Tiffany a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TIF - FREE

TheStreet Quant Ratings rates Tiffany as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins, good cash flow from operations, increase in net income and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Tiffany Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Salesforce.com (CRM) - FREE Research Report

Fisher Stephen, who is EVP, Technology at Salesforce.com, sold 6,725 shares at $53.10 on May 30, 2014. Following this transaction, the EVP, Technology owned 0 shares meaning that the stake was reduced by 100% with the 6,725-share transaction.

The shares most recently traded at $52.04, down $1.06, or 2.04% since the insider transaction. Historical insider transactions for Salesforce.com go as follows:

  • 4-Week # shares sold: 1,600
  • 12-Week # shares sold: 6,782
  • 24-Week # shares sold: 31,582

The average volume for Salesforce.com has been 7.0 million shares per day over the past 30 days. Salesforce.com has a market cap of $33.4 billion and is part of the technology sector and computer software & services industry. Shares are down 4.64% year-to-date as of the close of trading on Friday.

salesforce.com, inc. provides enterprise cloud computing solutions to various businesses and industries worldwide. Currently, there are 26 analysts who rate Salesforce.com a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CRM - FREE

TheStreet Quant Ratings rates Salesforce.com as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and generally higher debt management risk. Get the full Salesforce.com Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Ironwood Pharmaceuticals (IRWD) - FREE Research Report

Higgins Michael J, who is Chief Operating Officer at Ironwood Pharmaceuticals, sold 50,000 shares at $14.56 on May 30, 2014. Following this transaction, the Chief Operating Officer owned 0 shares meaning that the stake was reduced by 100% with the 50,000-share transaction.

The shares most recently traded at $13.84, down $0.72, or 5.2% since the insider transaction.

The average volume for Ironwood Pharmaceuticals has been 1.5 million shares per day over the past 30 days. Ironwood Pharmaceuticals has a market cap of $1.7 billion and is part of the health care sector and drugs industry. Shares are up 23.34% year-to-date as of the close of trading on Friday.

Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, discovers, develops, and commercializes human therapeutic products. Currently, there are 5 analysts who rate Ironwood Pharmaceuticals a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IRWD - FREE

TheStreet Quant Ratings rates Ironwood Pharmaceuticals as a sell. The area that we feel has been the company's primary weakness has been its disappointing return on equity. Get the full Ironwood Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing